StockNews.com Begins Coverage on Affimed (NASDAQ:AFMD)
StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. AFMD has been the subject of several other reports. Truist Financial reduced their target price on Affimed from $8.00 to $6.00 and set a buy […]